Latest & greatest articles for Tipranavir

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Tipranavir or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Tipranavir and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Tipranavir

1. Tipranavir (Aptivus®) oral solution

Tipranavir (Aptivus®) oral solution Tipranavir (Aptivus®) oral solution Tipranavir (Aptivus®) oral solution All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Tipranavir (Aptivus®) oral solution. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat (...) of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2110. 2010 Authors' conclusions Tipranavir (Aptivus®) oral solution, co-administered with low dose ritonavir, is recommended as an option for use within NHS Wales for combination antiretroviral treatment of HIV-1 infection in highly pre-treated children from 2 to 12 years of age with virus resistant to multiple protease inhibitors. Tipranavir (Aptivus®) should only be used as part of an active combination

2010 Health Technology Assessment (HTA) Database.

2. Tipranavir (Aptivus®) capsules

Tipranavir (Aptivus®) capsules Tipranavir (Aptivus®) capsules Tipranavir (Aptivus®) capsules All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Tipranavir (Aptivus®) capsules. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines (...) Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2010. 2010 Authors' conclusions Tipranavir (Aptivus®) capsules, co-administered with low dose ritonavir, are recommended as an option for use within NHS Wales, for combination antiretroviral treatment of HIV-1 infection in highly pre-treated adolescents 12 years of age or older with virus resistant to multiple protease inhibitors. Tipranavir (Aptivus®) should only be used as part of an active combination antiretroviral regimen

2010 Health Technology Assessment (HTA) Database.

3. Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States

Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States Simpson K N, Roberts G, Hicks C B, Finnern H W Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of tipranavir plus ritonavir (TPVr) in comparison with one of a selection of protease inhibitors plus ritonavir (CPIr) for the treatment of human immunodeficiency virus (HIV)-1-infected patients, who had received extensive treatment. The authors concluded that TPVr was a cost-effective alternative to CPIr from

2008 NHS Economic Evaluation Database.

4. Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands (Full text)

Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy (...) of ritonavir-boosted tipranavir (TPVr) compared with a ritonavir-boosted protease inhibitor (CPIr) in regimens for HIV infected patients, who had previously received antiretroviral therapy. The cost-effectiveness of TPVr over CPIr was approximately EUR 40,000, which might be acceptable from the perspective of the Dutch health care payer. The study was well conducted and satisfactorily presented. In general, the authors’ conclusions appear to be valid and robust. Type of economic evaluation Cost

2007 NHS Economic Evaluation Database. PubMed

5. Tipranavir (Aptivus®)

Tipranavir (Aptivus®) Tipranavir (Aptivus®) Tipranavir (Aptivus®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Tipranavir (Aptivus®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG (...) Secretariat Assessment Report Advice No. 0707. 2007 Authors' conclusions Tipranavir (Aptivus®) should be recommended for use within NHS Wales for the treatment of human immunodeficiency virus (HIV-1) infection, only for the treatment of highly pre-treated adult patients who have failed multiple protease inhibitors (PI), and where resistance profiling suggests it is appropriate. Use should be in accordance with the British HIV Association (BHIVA) guidance. Tipranavir (Aptivus®) is not presently recommended

2007 Health Technology Assessment (HTA) Database.

6. Tipranavir

Tipranavir Common Drug Review CEDAC Meeting – April 19, 2006 Page 1 of 2 Notice of CEDAC Final Recommendation – May 17, 2006 CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION TIPRANAVIR (Aptivus ® - Boehringer Ingelheim (Canada) Inc.) Description: Tipranavir is a nonpeptidic HIV-1 protease inhibitor (PI) which, in combination with low dose ritonavir, is approved for the treatment of adult patients with HIV-1 infection with evidence of viral replication, who are treatment experienced (...) and have HIV-1 strains resistant to multiple PIs. Dosage Forms: 250 mg capsule Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that tipranavir be listed as an alternate PI as part of a HIV treatment regimen in the treatment of adult patients with HIV-1 infection who are treatment experienced, have demonstrated failure to multiple PIs and in whom no other PI is a treatment option. Reasons for the Recommendation: 1. The Committee considered the results of two open-label

2006 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

7. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSista (PubMed)

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSista Treatment options for HIV-1 infected individuals who have received extensive previous antiretroviral therapy are limited. We compared efficacy and safety of the novel non-peptidic protease inhibitor tipranavir co-administered with ritonavir (...) primary resistance to protease inhibitor, were eligible. Primary endpoints were proportion of treatment responders (with reduction in viral load of 1 log(10) copies per mL or greater below baseline without treatment change) at 48 weeks and time to treatment failure through 48 weeks (intention-to-treat analysis). The RESIST studies are registered with ClinicalTrials.gov, numbers NCT00054717 (RESIST-1) and NCT00144170 (RESIST-2).3324 patients were screened; 746 received tipranavir-ritonavir and 737 CPI

2006 Lancet

8. Aptivus (tipranavir)

Aptivus (tipranavir) 1/37 ? EMEA 2005 SCIENTIFIC DISCUSSION 1. Introduction The World Health Organisation (WHO) estimated that there were at least 40 million people worldwide with Human Immunodeficiency virus (HIV) infection in 2004, and that 6 million needed treatment. Current treatment options consist of four different mechanistic classes of compounds: • NRTIs (nucleoside/nucleotide reverse transcriptase inhibitors) inhibiting the reverse transcriptase (RT) of HIV by structural similarity (...) dosing schedules or formulations. Further therapeutic agents are therefore needed, particularly in patients who have failed their therapy. APTIVUS which contains tipranavir, a non-peptidic protease inhibitor has been developed for treatment-experienced patients who have HIV-1 strains with PI resistance associated mutations (PRAMs). A so-called stand alone application has been submitted for registration. APTIVUS is available as 250 mg soft capsules. The recommended dose is 500 mg to be co-administered

2005 European Medicines Agency - EPARs